IOT.V Innovotech Inc
- Market cap
- CAD 3.27M
- P/E
- -
- P/B
- 1.28x
- ROE
- -82.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IOT.V undervalued?
Graham numberThe Graham number of Innovotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innovotech Inc fundamental analysis
No fundamental analysis for Innovotech Inc yet.
Innovotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract resear…
Full company profileInnovotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innovotech Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01M | 990K | 827K | 986K | 1.19M | 1.48M | 1.13M | 1.18M | 2.19M | 4.53M | 2.66M |
| Gross Profit | 733K | 700K | 606K | 695K | 867K | 1.12M | 780K | 482K | 1.11M | 2.40M | 428K |
| Operating Income | 86.1K | 36.0K | -127K | -19.9K | 99.3K | 268K | -140K | -380K | 48.1K | 23.9K | -2.16M |
| EBITDA | - | 798K | -112K | -29.5K | 127K | 442K | -17.3K | -78.8K | 286K | 264K | -1.84M |
| Net Income | -216K | 753K | -128K | -48.8K | 106K | 367K | -137K | -158K | 225K | 94.4K | -2.11M |
| EPS | - | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 325K | 527K | 272K | 275K | 822K | 1.43M | 1.22M | 1.22M | 3.22M | 4.43M | 3.59M |
| Total Liabilities | 1.54M | 346K | 179K | 177K | 177K | 256K | 165K | 218K | 597K | 785K | 994K |
| Shareholders' Equity | -1.22M | 182K | 93.5K | 98.1K | 645K | 1.18M | 1.06M | 931K | 2.57M | 3.60M | 2.54M |
| Cash & Short-term Investments | 33.2K | 325K | 28.8K | 96.7K | 530K | 422K | 469K | 161K | 725K | 1.62M | 375K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.32K | -159K | -281K | 76.3K | 175K | 25.0K | 208K | -228K | -81.6K | -62.4K | -1.18M |
| Capital Expenditure | 13.7K | 13.7K | 9.32K | 2.44K | 37.7K | 60.1K | 71.5K | 42.9K | 202K | 472K | 1.36M |
| Free Cash Flow | - | -172K | -290K | 73.9K | 138K | -35.1K | 137K | -271K | -284K | -534K | -2.54M |
| Ratios | |||||||||||
| ROE | - | 415.1% | -136.6% | -49.7% | 16.5% | 31.2% | -12.9% | -16.9% | 8.8% | 2.6% | -82.9% |
| ROA | -66.3% | 142.9% | -46.9% | -17.7% | 12.9% | 25.6% | -11.2% | -13.0% | 7.0% | 2.1% | -58.8% |
| Net Profit Margin | -21.4% | 76.1% | -15.4% | -4.9% | 8.9% | 24.8% | -12.1% | -13.3% | 10.2% | 2.1% | -79.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Innovotech Inc dividends
Innovotech Inc has not paid dividends in the last 9 fiscal years.
Who owns Innovotech Inc
- Insiders 41.88%
- Institutions 0.00%
- Public & others 58.13%
- Shares outstanding 54.4M
- Free float 30.9M
Innovotech Inc company profile
- Company name
- Innovotech Inc
- Ticker
- IOT.V
- ISIN
- CA45772U1049
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 2011-94 Street, Edmonton, AB, Canada, T6N 1H1
- Phone
- 780-448-0585
- Website
- innovotech.ca
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the sector of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.
Innovotech Inc management
6- Dr. James Timourian Ph.D.Independent Chairman & Secretary
- Dr. Craig Milne B.Sc., M.B.A., Ph.D.CEO, President & Director
- Mr. Craig KalvinChief Financial Officer
- Ms. Jodi McDonald B.Sc.Chief Operating Officer
- Mr. Roderick Szarka B.ScChief Commercial Officer
- Dr. Merle OlsonScientific Consultant